FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,360 | -55.5% | 28,000 | 0.0% | 0.01% | -53.8% |
| Q2 2023 | $133,280 | -16.5% | 28,000 | 0.0% | 0.01% | -23.5% |
| Q1 2023 | $159,600 | -43.5% | 28,000 | 0.0% | 0.02% | -45.2% |
| Q4 2022 | $282,520 | -54.9% | 28,000 | 0.0% | 0.03% | -55.7% |
| Q3 2022 | $627,000 | -27.8% | 28,000 | 0.0% | 0.07% | -18.6% |
| Q2 2022 | $869,000 | -20.0% | 28,000 | 0.0% | 0.09% | -15.7% |
| Q1 2022 | $1,086,000 | -10.4% | 28,000 | 0.0% | 0.10% | -6.4% |
| Q4 2021 | $1,212,000 | -29.3% | 28,000 | 0.0% | 0.11% | -28.3% |
| Q3 2021 | $1,715,000 | -29.4% | 28,000 | 0.0% | 0.15% | -37.4% |
| Q2 2021 | $2,430,000 | +5.2% | 28,000 | 0.0% | 0.24% | -6.9% |
| Q1 2021 | $2,309,000 | -9.3% | 28,000 | 0.0% | 0.26% | -22.6% |
| Q4 2020 | $2,546,000 | +138.6% | 28,000 | 0.0% | 0.34% | +106.7% |
| Q3 2020 | $1,067,000 | +3.6% | 28,000 | 0.0% | 0.16% | -6.3% |
| Q2 2020 | $1,030,000 | +65.6% | 28,000 | 0.0% | 0.17% | +1.8% |
| Q1 2020 | $622,000 | – | 28,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |